Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Endo Buys US Patent For Oxymorphone From Johnson Matthey - Quick Facts

RELATED NEWS
Trade ENDP now with 
3/22/2012 8:50 AM ET

Endo Pharmaceuticals Holdings (ENDP: Quote) said it has acquired U.S. patent for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc (JMAT.L).

By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.

"This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications," said Julie McHugh, chief operating officer of Endo.

Click here to receive FREE breaking news email alerts for Endo Health Solutions Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Housing starts in the U.S. showed a notable increase in the month of March, according to a report released by the Commerce Department on Wednesday, although starts still came in well below economist estimates. The report showed that housing starts climbed 2.8 percent to an annual rate of 946,000 in March from the revised February estimate of 920,000. After moving mostly higher over the course of the two previous sessions, stocks may see some further upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 63 points. The U.K. unemployment rate fell below the 7 percent threshold to a five-year low in February and average earnings finally moved above inflation reducing the squeeze on household finances. The jobless rate came in at 6.9 percent of the labor force, the lowest since February 2009, data from the Office for National Statistics showed Wednesday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.